A comprehensive analysis of FDA adverse event reports has identified a concerning safety signal: Wegovy carries approximately five times the risk of non-arteritic anterior ischemic optic neuropathy (NAION)—commonly called “eye stroke”—compared to Ozempic, despite both medications containing the same active ingredient, semaglutide.
Researchers examining over 15 million FDA adverse event reports between 2020 and 2024 identified 847 confirmed NAION cases during this period. The disparity appears directly linked to dosing differences: Wegovy is prescribed at higher concentrations (up to 2.4mg weekly) for weight management, while Ozempic typically uses lower doses (0.5-1mg weekly) for diabetes control.
NAION causes sudden, potentially permanent vision loss when blood flow to the optic nerve becomes blocked. Medical experts emphasize that patients taking Wegovy should remain vigilant for warning signs including sudden vision changes and seek immediate medical attention if symptoms develop. Read the full article on GMJ Newsroom.
Was this article helpful?
100% of readers found this helpful (1 votes)
